VCYT Veracyte, Inc.
Veracyte, Inc. (VCYT) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $742.6K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| EASTHAM KARIN | Director | Sell 10b5-1 | 14,850 | $50.00 | $742.6K | 10,247 −59.2% of holding | |
| Holstein Jens | Director | Sell 10b5-1 | 7,500 | $50.00 | $375.0K | 27,471 −21.4% of holding | |
| Bhanji Muna | Director | Sell 10b5-1 | 1,864 | $43.70 | $81.5K | 40,854 −4.4% of holding | |
| Holstein Jens | Director | Sell 10b5-1 | 7,500 | $47.00 | $352.5K | 27,471 −21.4% of holding | |
| Leite John | Global Chief Commercial Off | Sell 10b5-1 | 4,015 | $40.00 | $160.6K | 124,329 −3.1% of holding | |
| Holstein Jens | Director | Sell 10b5-1 | 5,000 | $40.95 | $204.7K | 27,471 −15.4% of holding | |
| Febbo Phillip G. 2 fills | Chief Scientific & Med Officer | Sell 10b5-1 | 13,110 | $43.05 | $564.4K | 135,753 −8.8% of holding | |
| Chambers Rebecca 2 fills | Chief Financial Officer | Sell 10b5-1 | 3,652 | $43.10 | $157.4K | 167,200 −2.1% of holding | |
| McGuire Annie 2 fills | EVP, General Counsel | Sell 10b5-1 | 3,254 | $43.09 | $140.2K | 132,260 −2.4% of holding | |
| Bhanji Muna | Director | Sell 10b5-1 | 1,864 | $42.97 | $80.1K | 42,718 −4.2% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.